Tardive dyskinesia in schizophrenic outpatients

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Phenothiazine antipsychotics are widely used for schizophrenia treatment.
• Tardive dyskinesia (TD) is a serious potential side effect of long-term antipsychotic use.
• Prevalence rates of TD vary significantly across studies and populations.

Purpose of the Study:

• To determine the prevalence of tardive dyskinesia in schizophrenic patients undergoing phenothiazine treatment.
• To investigate potential risk factors associated with tardive dyskinesia in this patient cohort.

Main Methods:

• A cohort of 211 schizophrenic patients receiving phenothiazine treatment was assessed.
• The Simpson Scale was utilized to diagnose and rate the severity of tardive dyskinesia.
• Patients were compared to a control group without tardive dyskinesia.

Main Results:

• The study identified 21 cases of tardive dyskinesia, resulting in a prevalence of 10%.
• This prevalence is notably lower than reported in many previous studies.
• No statistically significant relationships were observed between tardive dyskinesia and sex, age, treatment duration, ECT, benzhexol, or anticholinergic use.

Conclusions:

• The observed 10% prevalence of tardive dyskinesia suggests a potentially lower risk in this specific patient population compared to Western studies.
• Further research is needed to understand the factors contributing to this lower prevalence and to confirm findings in diverse populations.
• Clinical monitoring for tardive dyskinesia remains crucial in patients treated with phenothiazines.